Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. We discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). We are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. Our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines.
Company Growth (employees)
Type
Public
HQ
Cambridge, US
Size (employees)
674 (est)+43%
Ironwood Pharmaceuticals is headquartered in Cambridge, US

Key People at Ironwood Pharmaceuticals

Peter M. Hecht

Peter M. Hecht

Co-Founder
Brian M. Cali

Brian M. Cali

Co-Founder and Vice President of Program Management
Joseph C. Cook

Joseph C. Cook

Co-Founder and Chairman
Gina Bornino Miller

Gina Bornino Miller

Co-Founder and Director
George Conrades

George Conrades

Director

Ironwood Pharmaceuticals Office Locations

Ironwood Pharmaceuticals has office in Cambridge
Cambridge, US

Ironwood Pharmaceuticals Metrics

Ironwood Pharmaceuticals Summary

Market capitalization

$2.5 b

Closing share price

$17.6
Ironwood Pharmaceuticals's current market capitalization is $2.5 b.

Ironwood Pharmaceuticals Financials

Ironwood Pharmaceuticals's revenue is $274 m in FY, 2016 which is a 83.2% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$22.9 m$76.4 m$149.6 m$274 m

Revenue growth, %

234.1%95.7%83.2%

Gross profit

$15.7 m$50.9 m$149.5 m

Operating expense total

$267.7 m$220.2 m$251.6 m

EBIT

($252 m)($169.4 m)($102.1 m)

Net Income

($272.8 m)($189.6 m)($142.7 m)($81.7 m)

Operating cash flow

($61.2 m)($1.2 m)$187 m

Ironwood Pharmaceuticals Market Value History

Ironwood Pharmaceuticals Online Presence

Ironwood Pharmaceuticals Company Life

You may also be interested in